HLD 400

Drug Profile

HLD 400

Alternative Names: HLD400

Latest Information Update: 01 Jun 2016

Price : $50

At a glance

  • Originator Highland Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Inflammatory bowel diseases

Most Recent Events

  • 26 May 2016 Highland Therapeutics plans a phase I trial for Inflammatory bowel disease
  • 26 Apr 2016 Clinical development for Inflammatory bowel disease (unspecified route) before April 2016 (Highland Therapeutics pipeline, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top